Luteolin-loaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies

  • Hao Dang
  • Murtaza Hasan Weiwei Meng
  • Haiwei Zhao
  • Javed Iqbal
  • Rongji Dai
  • Yulin Deng
  • Fang Lv
Research Paper
First Online:
Received:
Accepted:

Abstract

Luteolin (LU, 5,7,3′,4′-tetrahydroxyflavone) most active compound in Chinese herbal flavones has been acting as a antimicrobial, anti-inflammatory, anti-cancer, and antimutagen. However, its poor bioavailability, hydrophobicity, and pharmacokinetics restrict clinical application. Here in this study, LU-loaded solid lipid nanoparticles have been prepared by hot-microemulsion ultrasonic technique to improve the bioavailability & pharmacokinetics of compound. LU-loaded solid lipid nanoparticle size was confirmed by particle size analyzer with range from 47 to 118 nm, having zepta potential −9.2 mV and polydisperse index 0.247, respectively. Round-shaped SLNPs were obtained by using transmission electron microscope, and encapsulation efficiency 74.80 % was calculated by using HPLC. Both in vitro and vivo studies, LC–MS/MS technique was used for quantification of Luteolin in rat. The T max value of drug with LU–SLNs after the administration was Ten times shorter than pure Luteolin suspension administration. C max value of drug after the administration of LU–SLNs was five times higher than obtained with native drug suspension. Luteolin with SLNs has increased the half-life approximately up to 2 h. Distribution and clearance of drug with SLNs were significantly decreased by 2.16–10.57 fold, respectively. In the end, the relative bioavailability of SLNs has improved about 4.89 compared to Luteolin with SLNs. From this study, it can be concluded that LU–SLNs have not only great potential for improving solubility but also increased the drug concentration in plasma. Furthermore, use of LC–MS/MS for quantification of LU–SLNs in rat plasma is reliable and of therapeutic usefulness, especially for neurodegenerative and cancerous disorders in humans.

Keywords

SLNs LC–MS/MS Bioavailability Pharmacokinetics Drug delivery Nanomedicine 

Abbreviations

TEM

Transmission electron microscopy

SLNs

Solid lipid nanoparticles

GMS

Glycero monostearate

DLS

Dynamic light scattering

EE

Entrapment efficiency

This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

The authors wish to express their thanks for financial support from the National Natural Science Foundation of China (No. 11079054), material and facilitative support from Beijing BIT&GY Pharmaceutical R&D Co. Ltd., P.R. China.

References

  1. Aggarwal N, Goindi S (2013) Preparation and in vivo evaluation of solid lipid nanoparticles of griseofulvin for dermal use. J Biomed Nanotechnol 9:564–576CrossRefGoogle Scholar
  2. Ajazuddin SS (2010) Application of novel drug delivery system for herbal formulations. Fitoterapia 81:680–689CrossRefGoogle Scholar
  3. Ariga K, Ji Q, Hill JP, Bando Y, Aono M (2012a) Forming nanomaterials as layered functional structures toward materials nano architectonics. NPG Asia Mater 4:e17CrossRefGoogle Scholar
  4. Ariga K, Vinu A, Yamauchi Y, Qingmin J (2012b) Nano architectonics for mesoporous materials. Bull Chem Soc Jpn 85:158–176CrossRefGoogle Scholar
  5. Chattopadhyay P, Shekunov BY, Yim D, Cipolla D, Boyd B, Farr S (2007) Production of solid lipid nanoparticle suspension using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv Drug Deliv Rev 59:444–453CrossRefGoogle Scholar
  6. Chen K, Xue D (2012) Nanoparticles via crystallization: a chemical reaction control study of copper oxides. Nanosci Nanotechnol Lett 4:1–12CrossRefGoogle Scholar
  7. Chen T, Li LP, Lu XY, Jiang HD, Zeng S (2007) Absorption and excretion of luteolin and apigenin in rats after oral administration of Chrysanthemum morifolium extract. J Agric Food Chem 55:277–284Google Scholar
  8. Dirscherl K, Karlstetter M, Ebert S, Kraus D, Hlawatsch J, Walczak Y, Moehle C, Fuchshofer R, Langmann T (2010) Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. J Neuroinflammation 7(3):102–118Google Scholar
  9. Gao Y, Wang C, Sun M, Wang X, Yu A, Li A, Zhai G (2012) In vivo evaluation of curcumin loaded nano suspensions by oral administration. J Biomed Nanotechnol 8:659–668CrossRefGoogle Scholar
  10. Jeon YW, Suh YJ (2013) Synergistic apoptosis effect of celecoxib and luteolin on breast cancer cell. Oncol Rep 29(2):825–832Google Scholar
  11. Jian SR, Ke WC, Juang JY (2012) Mechanical characteristics of Mg-doped GaN thin films by Nano indentation. Nanosci Nanotechnol Lett 4:593–598CrossRefGoogle Scholar
  12. Kang OH, Choi JG, Lee JH, Kwon DY (2010) Luteolin isolated from the flower of Lonicera japonica suppresses inflammatory mediator release by blocking NF-B MAPK activation pathways in HMC-1 cells. Molecules 15:385–398CrossRefGoogle Scholar
  13. Kheradmandnia S, Vasheghani-Farahani E, Nosrati M, Atyabi F (2010) Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax. Nanomed Nanotechnol Biol Med 6:753–759CrossRefGoogle Scholar
  14. Kim SW, Kim T, Kim YS, Choi HS, Lim HJ, Yang SJ, Park CR (2012) Grafting Polymer coating on to surface of carbon nanotubes. Carbon 50:1–3CrossRefGoogle Scholar
  15. Kumari A, Yadav SK, Yadav SC (2010) Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 75:1–18CrossRefGoogle Scholar
  16. Lapenda TLS, Morais WA, Almeida FJF, Ferraz MS, Lira MCB, Santos MPS, Macie MAM, Santos-Magalhaes NS (2013) Encapsulation of trans-dehydrocrotonin in Liposomes: an enhancement of the antitumor activity. J Biomed Nanotechnol 9:499–510CrossRefGoogle Scholar
  17. Lazaro ML (2009) Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem 9:31–59CrossRefGoogle Scholar
  18. Lee S, Seo DH, Park HL, Choi Y, Jung S (2003) Solubility enhancement of a hydrophobic flavonoid, luteolin by the complexation with cyclosophoraoses isolated from Rhizobium meliloti. Antonie Van Leeuwenhoek 84(3):207CrossRefGoogle Scholar
  19. Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H (2009) Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 133:238–244CrossRefGoogle Scholar
  20. Licciardi M, Scialabba C, Cavallaro G, Sangregorie C, Fantechi E, Giammona G (2013) Cell uptake enhancement of folate targeted polymer coated magnetic nanoparticles. J Biomed Nanotechnol 9:949–964CrossRefGoogle Scholar
  21. Liu R, Meng F, Zhang L, Liu A, Qin H, Lan X, Du LG (2011) Luteolin isolated from the medicinal plant Elsholtzia rugulosa (Labiatae) prevent copper mediated toxicity in beta amyloid precursor protein swedish mutation overexpressing Sh-SY5Y cells. Molecules 16:2084–2096CrossRefGoogle Scholar
  22. Luo YF, Chen DW, Ren LX, Zhao XL et al (2006) Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability. J Control Release 114:53–59CrossRefGoogle Scholar
  23. Madhu B, Raju J, Karthik YJ, Sharath S, Ashok V, Srinivas A, Jayaveera KN (2013) Enhanced intestinal absorption and bioavailability of raloxifene hydrochloride via lyophilized solid lipid nanoparticles. Adv Powder Technol 24:393–402CrossRefGoogle Scholar
  24. Manosroi A, Chankhampan C, Manosroi W, Manosroi J (2012) Toxicity reduction and MMP-2 stimulation of papain and bromelain loaded in elastic niosomes. J Biomed Nanotechnol 8:720–729CrossRefGoogle Scholar
  25. Manosroi A, Chaikul P, Abe M, Manosroi W, Manosroi J (2013) Melanogenesis of methyl myristate loaded niosomes in B16F10 melanoma cells. J Biomed Nanotechnol 9:625–638Google Scholar
  26. Mehnert W, Mader K (2001) Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 47:165–196CrossRefGoogle Scholar
  27. Mirza MA, Agarwal SP, Iqbal Z (2011) Effect of fulvic acid on oral delivery of carbamazepine sci. Adv Mater 3:223–232CrossRefGoogle Scholar
  28. Murtaza H, Zhongqiu T, Javed I, Umer A, Shiying M, Rongji D, Hong Q, Yulin D (2013) Assessment of bioreducing and stabilizing potential of Dragon’s blood (Dracaena Cochinchinensis, Lour. S. C. Chen) resin extract in synthesis of silver nanoparticles. Nanosci Nanotechnol Lett 5(7):780–784CrossRefGoogle Scholar
  29. Nagy M, Kova LK, Mucaji P, Kontsekova Z, Sersen S, Krajcovic J (2009) Antimutagenic activity and radical scavenging activity of water infusion and phenolics from ligustrum plant leaves. Molecules 14:509–518CrossRefGoogle Scholar
  30. Naiwa HS (ed) (2000) Handbook of nanostructural materials and nanotechnology. Academic Press, New York, pp 1–5Google Scholar
  31. Ozgen U, Ahmet M, Zeynep T, Cavit K, Ali A, Yusuf K, Hasan S (2011) Anto-oxidant and microbial activity. S Afr J Bot 5:1–21Google Scholar
  32. Paliwa R, Rai S, Vyas SP (2011) Lipid drug conjugate (LDC) nanoparticles as autolymphotrophs for oral delivery of methotrexate. J Biomed Nanotechnol 7:130–131CrossRefGoogle Scholar
  33. Paliwal R, Rai S, Vaidya B, Khatri K, Goyal AK, Mishra N, Mehta A, Vyas SP (2009a) Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomed Nanotechnol Biol Med 5:184–191CrossRefGoogle Scholar
  34. Paliwal R, Rai S, Vaidya B, Khatri K, Goyal AK, Mishra N, Mehta A, Vyas SP (2009b) Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine 5:184–191CrossRefGoogle Scholar
  35. Rai S, Paliwal R, Gupta PN, Khatri K, Goyal K, Vaidya B, Vyas SP (2008) Solid lipid nanoparticles (SLNs) as a rising too in drug delivery science: one step up in nanotechnology. Curr Nanosci 4:30–44CrossRefGoogle Scholar
  36. Rejinold NS, Muthunarayanan M, Chennazhi KP, Nair SV, Jayakumar R (2011) Curcumin loaded, fibrinogen nanoparticles for cancer drug delivery. J Biomed Nanotechnol 7:521–534CrossRefGoogle Scholar
  37. Rishi P, Shivani RP, Govind PA, Suresh PV (2011) Biomimetic solid lipid nanoparticles for oral bioavailability enhancement of low molecular weight heparin and its lipid conjugates: in vitro and in vivo Evaluation. Mol Pharm 8:1314–1321CrossRefGoogle Scholar
  38. Sharma P, Dube D, Sawant K (2012) Synthesis of cytarabine lipid drug conjugate for treatment of meningeal leukemia: Development, characterization and in vitro cell line studies. J Biomed Nanotechnol 8:928–937CrossRefGoogle Scholar
  39. Shengpeng W, Tongkai C, Ruie C, Yangyang H, Meiwan C, Yitao W (2012) Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies. Int J Pharm 430:238–246CrossRefGoogle Scholar
  40. Souto EB (2009) A special on lipid based delivery system (liposomes, lipid nanoparticles, lipid matrices and medicines). J Biomed Nanotechnol 5:315–316CrossRefGoogle Scholar
  41. Suresh G, Manjunath K, Venkateswarlu V, Satyanarayana V (2007) Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS Pharm Sci Tech 8:162–170CrossRefGoogle Scholar
  42. Suzgec SS, Birteksoz AS (2011) Flavonoids of Helichrysum chasmolycicum and its antioxidant and antimicrobial activities. S Afr J Bot 77(1):170–174CrossRefGoogle Scholar
  43. Vandita K, Si S, Dinesh S, Indu PK (2011) Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res 55:495–503CrossRefGoogle Scholar
  44. Waghmare AS, Grampurohit ND, Gadhave MV, Gaikwad DD, Jadhav SI (2001) Solid lipid nanoparticles: a promising drug delivery system. IRJP 3(4):100–107Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Hao Dang
    • 1
  • Murtaza Hasan Weiwei Meng
    • 1
  • Haiwei Zhao
    • 1
  • Javed Iqbal
    • 1
  • Rongji Dai
    • 1
  • Yulin Deng
    • 1
  • Fang Lv
    • 1
  1. 1.School of Life SciencesBeijing Institute of Technology (BIT)BeijingPeople’s Republic of China

Personalised recommendations